RESEARCH TRIANGLE PARK – GlaxoSmithKline’s CEO is under growing pressure to deliver better results for the drug giant, which has significant operations in the Triangle region.
Questioned about the company’s financial performance and plans to divid the firm, Emma Walmsley told reporters on Wednesday:
“I’m not a scientist, I’m a business leader,” she said. “Ultimately the CEO should be held accountable for the results, and that’s why we are extremely focused with a very committed team to delivering shareholder value. We have made an enormous amount of change in this supertanker of a company.”
GSK on Wednesday reported a big drop in revenue.
Elliott Management had built up a sizeable stake in the British drugmaker, according to media reports.
The Guardian says Elliott Management is an “aggressive activist” investor.
“The hedge fund petitioned for the sale of Alexion Pharmaceuticals ahead of its subsequent acquisition by AstraZeneca in December 2020,” reports PMLive.
